CytomX Therapeutics (CTMX) vs Evotec (EVO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CytomX Therapeutics (CTMX) has outperformed Evotec (EVO) over the past year, losing 23.4% versus a loss of 58.9%. Over five years, CTMX leads with a -50.4% price change compared with -92.9% for EVO. Evotec is the larger company by market cap ($572.2 million vs $555.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTMX | EVO |
|---|---|---|
| Share price | $2.55 | $1.61 |
| Market cap | $555.64M | $572.18M |
| 1-day change | -0.39% | -1.23% |
| YTD return | -40.14% | -47.73% |
| 1-year return | -23.42% | -58.93% |
| 5-year return | -50.39% | -92.87% |
| EPS (TTM) | $-0.51 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.21 | $4.27 |
| 52-week low | $2.48 | $1.50 |
| Distance from 52-week high | -68.94% | -62.30% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +380.39% | +158.39% |
| Average volume | 3.36M | 104.15K |
| Shares outstanding | 217.90M | 355.39M |
| Employees | 69 | 4,461 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CTMX has outperformed EVO by 35.5 percentage points over the past year.
About CytomX Therapeutics
CTMX stock →CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Evotec
EVO stock →Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics.
Health Care · Biotechnology: Pharmaceutical Preparations · 4,461 employees
CTMX vs EVO FAQ
Which is bigger, CytomX Therapeutics or Evotec?
Evotec (EVO) is larger, with a market capitalization of $572.18M compared with $555.64M for CytomX Therapeutics (CTMX).
Which stock has performed better over the past year, CTMX or EVO?
CTMX returned -23.42% over the past 12 months, compared with -58.93% for EVO (price return, excluding dividends). Past performance does not predict future results.
Are CytomX Therapeutics and Evotec in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.